New insights into the use of biomarkers of diabetic nephropathy

Advances in Chronic Kidney Disease

Volumn 21, Issue 3, 2014, Pages 318-326

  Jha, Jay C ^a   Jandeleit Dahm, Karin A M ^a   Cooper, Mark E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Biomarkers; Diabetes; Diabetic nephropathy; Metabolomics; Proteomics

Indexed keywords

ADIPONECTIN; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CERULOPLASMIN; COLLAGEN TYPE 4; FATTY ACID BINDING PROTEIN; KIM 1 PROTEIN; LAMININ; MEMBRANE PROTEIN; NAG PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RETINOL BINDING PROTEIN 4; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALBUMINURIA; ARTICLE; DIABETIC NEPHROPATHY; GLOMERULAR INJURY; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; NEPHRITIS; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEOMICS; METABOLISM; METABOLOMICS;

ALBUMINURIA; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; METABOLOMICS; PROTEOMICS;

EID: 84899501707     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.03.008     Document Type: Review

References (88)

1. Roglic G., Unwin N., Bennett P.H., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28(9):2130-2135.
2. Molitch M.E., DeFronzo R.A., Franz M.J., et al. Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl 1):S79-S83.
3. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352(9123):213-219.
4. Brenner B.M., Hostetter T.H., Humes H.D. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978, 298(15):826-833.
5. Forbes J.M., Coughlan M.T., Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57(6):1446-1454.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
7. Kaneto H., Katakami N., Kawamori D., et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007, 9(3):355-366.
8. Gill P.S., Wilcox C.S. NADPH oxidases in the kidney. Antioxid Redox Signal 2006, 8(9-10):1597-1607.
9. Palicz A., Foubert T.R., Jesaitis A.J., Marodi L., McPhail L.C. Phosphatidic acid and diacylglycerol directly activate NADPH oxidase by interacting with enzyme components. J Biol Chem 2001, 276(5):3090-3097.
10. Moresco R.N., Sangoi M.B., De Carvalho J.A., Tatsch E., Bochi G.V. Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta 2013, 421:17-30.
11. Keane W.F., Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999, 33(5):1004-1010.
12. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77(1):57-64.
13. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63(1):225-232.
14. Yokoyama H., Araki S., Haneda M., et al. Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 2012, 55(7):1911-1918.
15. Cohen-Bucay A., Viswanathan G. Urinary markers of glomerular injury in diabetic nephropathy. Int J Nephrol 2012, 2012:146987.
16. Macisaac R.J., Tsalamandris C., Thomas M.C., et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006, 49(7):1686-1689.
17. Kanauchi M., Akai Y., Hashimoto T. Transferrinuria in type 2 diabetic patients with early nephropathy and tubulointerstitial injury. Eur J Intern Med 2002, 13(3):190-193.
18. Jerums G., Cooper M.E., Seeman E., Murray R.M., McNeil J.J. Spectrum of proteinuria in type I and type II diabetes. Diabetes Care 1987, 10(4):419-427.
19. Jerums G., Allen T.J., Cooper M.E. Triphasic changes in selectivity with increasing proteinuria in type 1 and type 2 diabetes. Diabet Med 1989, 6(9):772-779.
20. Yaqoob M., McClelland P., Patrick A.W., Stevenson A., Mason H., Bell G.M. Tubular damage in microalbuminuric patients with primary glomerulonephritis and diabetic nephropathy. Ren Fail 1995, 17(1):43-49.
21. von Eynatten M., Liu D., Hock C., et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 2009, 58(9):2093-2099.
22. Saraheimo M., Forsblom C., Thorn L., et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008, 31(6):1165-1169.
23. Sharma K., Ramachandrarao S., Qiu G., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118(5):1645-1656.
24. Narita T., Sasaki H., Hosoba M., et al. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004, 27(5):1176-1181.
25. Narita T., Hosoba M., Kakei M., Ito S. Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29(1):142-144.
26. Qin L.X., Zeng X., Huang G. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004, 29(2):208-211.
27. Hong C.Y., Chia K.S. Markers of diabetic nephropathy. J Diabetes Complications 1998, 12(1):43-60.
28. Inoue M., Oishi C., Shimajiri Y., Furuta M., Ueyama M., Sanke T. Rinsho Byori 2008, 56(7):564-569.
29. Nakamura T., Ushiyama C., Suzuki S., et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15(9):1379-1383.
30. Wang G., Lai F.M., Lai K.B., Chow K.M., Li K.T., Szeto C.C. Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract 2007, 106(4):c169-c179.
31. Hara M., Yamagata K., Tomino Y., et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 2012, 55(11):2913-2919.
32. Nielsen J.S., McNagny K.M. The role of podocalyxin in health and disease. J Am Soc Nephrol 2009, 20(8):1669-1676.
33. Koop K., Eikmans M., Baelde H.J., et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003, 14(8):2063-2071.
34. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14(10):2534-2543.
35. Nielsen S.E., Schjoedt K.J., Astrup A.S., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabetic Med 2010, 27(10):1144-1150.
36. Nielsen S.E., Reinhard H., Zdunek D., et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012, 97(1):71-76.
37. Piwowar A., Knapik-Kordecka M., Fus I., Warwas M. Urinary activities of cathepsin B, N-acetyl-beta-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit 2006, 12(5):CR210-CR214.
38. Vaidya V.S., Niewczas M.A., Ficociello L.H., et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int 2011, 79(4):464-470.
39. Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008, 48:463-493.
40. Tesch G.H. Review: serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology (Carlton) 2010, 15(6):609-616.
41. Nielsen S.E., Andersen S., Zdunek D., Hess G., Parving H.H., Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011, 79(10):1113-1118.
42. Ekstrom B., Peterson P.A., Berggard I. A urinary and plasma alpha1-glycoprotein of low molecular weight: isolation and some properties. Biochem Biophys Res Commun 1975, 65(4):1427-1433.
43. Hong C.Y., Hughes K., Chia K.S., Ng V., Ling S.L. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003, 26(2):338-342.
44. Yoshikawa R., Wada J., Seiki K., et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 76(3):358-367.
45. Helaly M.A., Sheashaa H.A., Hatata el S.Z., Youssef A.B., Hegazi A., Abdel-Aal I.A. Endothelial dysfunction in geriatric diabetic patients: the role of microalbuminuria in elderly type 2 diabetic patients? A randomized controlled study. Int Urol Nephrol 2007, 39(1):333-338.
46. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008, 73(4):465-472.
47. Nielsen S.E., Sugaya T., Tarnow L., et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009, 32(9):1684-1688.
48. Ishimitsu T., Ohta S., Saito M., et al. Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol 2005, 9(1):34-39.
49. Panduru N.M., Forsblom C., Saraheimo M., et al. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, 36(7):2077-2083.
50. Nauta F.L., Boertien W.E., Bakker S.J., et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34(4):975-981.
51. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010, 29(4):357-365.
52. Hong C.Y., Chia K.S., Ling S.L. Urinary protein excretion in Type 2 diabetes with complications. J Diabetes Complications 2000, 14(5):259-265.
53. Kado S., Aoki A., Wada S., et al. Urinary type IV collagen as a marker forearly diabetic nephropathy. Diabetes Res Clin Pract 1996, 31(1-3):103-108.
54. Iijima T., Suzuki S., Sekizuka K., et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998, 12(6):378-382.
55. Takizawa H., Satoh T., Kurusu A., et al. Increase of urinary type IV collagen in normoalbuminuric patients with impaired glucose tolerance. Nephron 1998, 79(4):474-475.
56. Cohen M.P., Lautenslager G.T., Shearman C.W. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care 2001, 24(5):914-918.
57. Tsakas S., Goumenos D.S. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 2006, 26(2):186-193.
58. Wong M.G., Perkovic V., Woodward M., et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2013, 83(2):278-284.
59. Wong C.K., Ho A.W., Tong P.C., et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 2007, 149(1):123-131.
60. Wada T., Furuichi K., Sakai N., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58(4):1492-1499.
61. Tashiro K., Koyanagi I., Saitoh A., et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002, 16(1):1-4.
62. Ortiz A., Egido J. Is there a role for specific anti-TNF strategies in glomerular diseases?. Nephrol Dial Transplant 1995, 10(3):309-311.
63. Niewczas M.A., Ficociello L.H., Johnson A.C., et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009, 4(1):62-70.
64. Navarro J.F., Mora C., Gomez M., Muros M., Lopez-Aguilar C., Garcia J. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. Nephrol Dial Transplant 2008, 23(3):919-926.
65. Nakamura A., Shikata K., Hiramatsu M., et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005, 28(12):2890-2895.
66. Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67(3):291-300.
67. Navarro J.F., Mora C., Muros M., Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006, 21(12):3428-3434.
68. Dechanet J., Grosset C., Taupin J.L., et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997, 159(11):5640-5647.
69. El-Asrar M.A., Adly A.A., Ismail E.A. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatr Diabetes 2012, 13(8):616-624.
70. Chiarelli F., Giannini C., Verrotii A., Mezzett A., Mohn A. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Diabetes Metab Res Rev 2008, 24(7):570-576.
71. Lajer M., Tarnow I., Michelson A.D., et al. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 2010, 21(7):525-532.
72. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107(9):1058-1070.
73. Oberg B.P., McMenamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65(3):1009-1016.
74. Wu L.L., Chiou C.C., Chang P.Y., Wu J.T. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004, 339(1-2):1-9.
75. Kanauchi M., Nishioka H., Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002, 91(2):327-329.
76. Calabrese V., Mancuso C., Sapienza M., et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007, 12(4):299-306.
77. Thuraisingham R.C., Nott C.A., Dodd S.M., Yaqoob M.M. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 2000, 57(5):1968-1972.
78. Sugiyama S., Miyata T., Ueda Y., et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998, 9(9):1681-1688.
79. Ben Ameur R., Molina L., Bolvin C., et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010, 25(9):2866-2875.
80. Thongboonkerd V. Study of diabetic nephropathy in the proteomic era. Contrib Nephrol 2011, 170:172-183.
81. Otu H.H., Can H., Spentzos D., et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30(3):638-643.
82. Starkey J.M., Tilton R.G. Proteomics and systems biology for understanding diabetic nephropathy. J Cardiovasc Transl Res 2012, 5(4):479-490.
83. Merchant M.L., Perkins B.A., Boratyn G.M., et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009, 20(9):2065-2074.
84. Zurbig P., Jerums G., Hovind P., et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61(12):3304-3313.
85. Roscioni S.S., de Zeeuw D., Hellemons M.E., et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013, 56(2):259-267.
86. Bhensdadia N.M., Hunt K.J., Lopes-Virella M.F., et al. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney Int 2013, 83(6):1136-1143.
87. Lewis G.D., Asnani A., Gerszten R.E. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 2008, 52(2):117-123.
88. Sharma K., Karl B., Mathew A.V., et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013, 24(11):1901-1912.